First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

Patrizia Tosi, Elena Zamagni, Claudia Cellini, Raffaele Parente, Delia Cangini, Paola Tacchetti, Giulia Perrone, Michela Ceccolini, Paola Boni, Sante Tura, Michele Baccarani, Michele Cavo

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences